Key result
Polypharmacy was strongly associated with an increased risk of dementia (pooled aRR 1.30; 95% CI 1.16-1.46), with excessive polypharmacy showing an even stronger association (aRR 1.52).
Why the study?
Is polypharmacy associated with an increased risk of dementia?
Meta-Analysis
Is polypharmacy associated with an increased risk of dementia?
Effect estimate: aRR 1.30 (95% CI 1.16-1.46)
Polypharmacy and excessive polypharmacy are significantly associated with an increased risk of dementia, highlighting the importance of medication review in cognitive assessments.
May inform cognitive risk assessment via medication review; leaves open causality and deprescribing benefits pending RCTs.
Objective: The association between polypharmacy and dementia is controversial. This systematic review and meta-analysis aims to summarize existing literature concerning the association between polypharmacy and dementia.Methods: A systematic literature review was performed by searching the EMBASE, PubMed, Scopus and International Pharmaceutical Abstract databases using terms related to polypharmacy and dementia. A meta-analysis was performed using random effect models.Results: Seven studies were included in this meta-analysis. The included studies were of medium to high quality with a potential for publication bias. A strong association between polypharmacy and dementia was found (pooled adjusted risk ratio (aRR) = 1.30 (95% CI: 1.16–1.46), I2 = 68%). Excessive polypharmacy was also strongly associated with dementia (pooled aRR = 1.52 (95% CI: 1.39–1.67), I2 = 24%).Conclusion: Pooled risk estimates from this meta-analysis showed that polypharmacy was associated with dementia. Although the causality of the relationship cannot be concluded from this analysis, the finding encourages the use of multidimensional assessment tools for dementia that includes the number of medications as a component.
No takes yet. Share an insight, caveat, or question.
Leelakanok et al. (2018) conducted a meta-analysis in Dementia. Polypharmacy was evaluated on Dementia (aRR 1.30, 95% CI 1.16-1.46). Polypharmacy was strongly associated with an increased risk of dementia (pooled aRR 1.30; 95% CI 1.16-1.46), with excessive polypharmacy showing an even stronger association (aRR 1.52).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: